A Study on Whether Patients Prefer the Spiriva® Respimat® or the Spiriva® Handihaler® for Treating Their Chronic Obstructive Pulmonary Disease (COPD)
Phase 4
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2019-05-28
- Last Posted Date
- 2023-10-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 72
- Registration Number
- NCT03964207
- Locations
- 🇨🇳
First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
🇨🇳Zhongshan Hospital Fudan University, Shanghai, China
🇨🇳The First Hospital of China Medical University, Shenyang, China
Impact of Tiotropium Add-on Therapy in Patients With Asthma
Completed
- Conditions
- Asthma
- Interventions
- Drug: Inhaled Corticosteroid/Long-acting beta-agonist
- First Posted Date
- 2019-05-28
- Last Posted Date
- 2020-11-03
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 7857
- Registration Number
- NCT03964220
- Locations
- 🇺🇸
eMax Health, White Plains, New York, United States
A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab)
Phase 1
Active, not recruiting
- Conditions
- Neoplasms
- Interventions
- First Posted Date
- 2019-05-28
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 120
- Registration Number
- NCT03964233
- Locations
- 🇫🇷
INS Bergonie, Bordeaux, France
🇫🇷CTR Leon Berard, Lyon, France
🇫🇷INS Gustave Roussy, Villejuif, France
A Study Based on Medical Records That Looks at the Characteristics of Idiopathic Pulmonary Fibrosis Patients Grouped by the Type of Medication They Are Taking
Completed
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- First Posted Date
- 2019-05-21
- Last Posted Date
- 2021-11-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 13264
- Registration Number
- NCT03958071
- Locations
- 🇺🇸
Plymouth Meeting, Plymouth, Pennsylvania, United States
Spiolto® Respimat® (Tiotropium/Olodaterol) Versus Triple Combination Therapy in Everyday Clinical Treatment Practice for Chronic Obstructive Pulmonary Disease (EVELUT®)
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Triple-Therapy (LAMA/LABA/ICS)
- First Posted Date
- 2019-05-17
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 469
- Registration Number
- NCT03954132
- Locations
- 🇩🇪
Dr. Graubner, Bad Sachsa, Germany
🇩🇪Dr. Kopf, Berlin, Germany
🇩🇪Dres. Bartels/Bartels, Breuberg, Germany
Global Atrophie Biomarker Evaluation Study (GABiE)
Terminated
- Conditions
- Age-related Macular Degeneration
- Interventions
- Diagnostic Test: Diagnostics
- First Posted Date
- 2019-05-02
- Last Posted Date
- 2021-05-21
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 3
- Registration Number
- NCT03935126
- Locations
- 🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States
🇨🇭University Hospital Basel, Basel, Switzerland
This Study in Healthy Men and Women Tests Whether BI 409306 Has an Effect on the ECG (Thorough QT Study)
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2019-05-01
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 47
- Registration Number
- NCT03934203
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany
A Study in Healthy Men to Test the Effects of Different Doses of BI 1467335 on MAO-B Activity in the Brain.
- First Posted Date
- 2019-04-25
- Last Posted Date
- 2021-06-22
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 10
- Registration Number
- NCT03927209
- Locations
- 🇬🇧
Northwick Park Hospital, Harrow, United Kingdom
A Study in Healthy Men That Tests if Taking BI 1265162 by Mouth, Intravenously, or Inhaled Influences the Amount of BI 1265162 in the Blood
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: BI 1265162 (T1)Drug: BI 1265162 (T2)Drug: BI 1265162 (R)Drug: BI 1265162 (T3)
- First Posted Date
- 2019-04-08
- Last Posted Date
- 2022-07-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 12
- Registration Number
- NCT03907280
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany
A Study in Healthy Men and Women to Test Which Effects Donepezil and BI 425809 Have on Each Other
- First Posted Date
- 2019-04-05
- Last Posted Date
- 2021-02-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 32
- Registration Number
- NCT03905096
- Locations
- 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany
© Copyright 2025. All Rights Reserved by MedPath